Community Research and Development Information Service - CORDIS

EU-funded project CARAT offers fellowships for its 2nd training course on CAR T cell manufacturing - Apply by June 30, 2018!

Contributed by: Eurice - European Research and Project Office GmbH

From 2018-06-30 to 2018-06-30, Germany
CARAT is taking on the mission to deliver new methods to enable the wide use of novel personalised cancer treatment options. In 2018, CARAT invites five scientists to participate in a unique training event at Miltenyi Biotec aiming to transfer knowledge on GMP compliant CAR T cell manufacturing to scientists in the field. Scientists with a profound background in cellular and gene therapy who intend to initiate clinical applications in the near future can apply for the fellowship by end of June.
EU-funded project CARAT offers fellowships for its 2nd training course on CAR T cell manufacturing - Apply by June 30, 2018!
The EU-funded project Chimeric Antigen Receptors (CARs) for Advanced Therapies (CARAT) aims to develop a new, comprehensive platform for innovative cell manufacturing technologies as part of the European Horizon 2020 research and innovation programme. In order to accomplish the goal of providing safe, automated and cost-efficient manufacture of effective CAR T cells for personalised cancer therapies, CARAT, consisting of eight partners from four European countries, was initiated. Within the framework of CARAT, two training courses on GMP-compliant CAR T cell manufacturing will be organised. After the successful 1st training event in 2017, the 2nd training event will take place in December 2018 at Miltenyi Biotec’s headquarters in Bergisch Gladbach, Germany.

The CARAT training fellowship
The fellowship is tailored towards experienced scientists in the cellular and gene therapy field, who expect to initiate clinical applications in the near future. The 5-day training course will transmit know-how on GMP-compliant CAR T cell manufacturing, with a focus on practical, regulatory and scientific matters, to five selected trainees. Objectives of the training event include an introduction to cell separation technology, a deep overview of the T cell transduction (TCT) process on the automated CliniMACS Prodigy® cell processing platform, and an active exchange about regulatory requirements including clinical trial design and approval processes. After the course, each CARAT trainee will be prepared to independently perform the automated manufacture of cellular products as well as manage logistical aspects such as GMP compliance and adherence to monitoring guidelines.

Important dates
Applicants from EU Member States and Associated Countries are encouraged to participate and submit their applications by June 30, 2018. Submitted applications will be carefully peer reviewed by the CARAT Steering Committee, considering the scientific background of applicants as well as gender balance and regional aspects. All applicants will be informed about the decision no later than 3 months after the submission deadline.

Contributor

Organisation

    Eurice - European Research and Project Office GmbH
    Science Park 1
    66123 Saarbücken
    Germany
    Website

Related information

Keywords

Fellowship, CAR T cells, cancer therapy, Chimeric Antigen Receptors, cell manufacturing, GMP compliant
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top